| P/E (FY) | — | Sales (TTM) | €29.6M |
| Earnings (TTM) | -€24.0M | ROE | — |
| Net Margin | −80.83% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 83.77% |
Nanobiotix S.A. is a clinical-stage biotechnology company working on product candidates for cancer and other unmet medical needs. Its lead candidate, NBTXR3, is a suspension of crystalline hafnium oxide nanoparticles being studied across cancers including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has partnered with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. It was incorporated in 2003 and is based in Paris, France.
| Market Cap | — | Trading Days | 3449 |
| 52W High | 47.60 |
| 52W Low | 5.57 |
| % Off High | −31.01% |
| YTD | 68.41% | 1Y | 477.15% |
| 3Y | 348.02% | 5Y | 173.67% |
| 10Y | 90.49% | Since incept. (ann.) | 12.90% |
| Ann. Volatility (1Y) | 88.10% | Ann. Volatility (3Y) | 76.82% |
| Sharpe (1Y) | 2.53 | Sharpe (3Y) | 1.03 |
| Max Drawdown (1Y) | −45.36% | Max Drawdown (3Y) | −72.39% |
| Beta (3Y, vs SPY) | 0.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| AMGN | AMGEN INC | $209.21B | 27.2 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| GILD | GILEAD SCIENCES, INC. | $164.79B | 19.6 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| SYK | STRYKER CORP | $135.04B | 41.9 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.85B | 18.2 |
| ISRG | INTUITIVE SURGICAL INC | $124.74B | 44.9 |
